Literature DB >> 321165

Restoration by levamisole of low E-rosette forming cells in patients suffering from various diseases.

H Verhaegen, J De Cree, W De Cock, F Verbruggen.   

Abstract

One hundred and fifteen patients presenting with various clinical conditions (multiple sclerosis, recurrent infections, HBAg-positive chronic hepatitis, Crohn's disease, ataxia-telangiectasia, SSPE and atopic dermatitis) were evaluated for E-rosette formation. Forty-two patients were found to have a low number of E-rosettes. Eighteen patients with low E-rosettes were treated with levamisole, an anti-anergic chemotherapeutic agent, and were compared with an untreated control group of sixteen patients. Levamisole treatment significantly increased low E-rosettes in these patients and this was accompanied by a remarkable clinical improvement and a significant reduction of haemolytic complement activity. Therefore our results suggest the important role of T-cell function in these various clinical conditions, in which cell-mediated immunity is thought to play a major role.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 321165      PMCID: PMC1540796     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Letter: Treatment of recurrent aphthous stomatitis and herpes with levamisole.

Authors:  J Symoens; J Brugmans
Journal:  Br Med J       Date:  1974-12-07

2.  Aetiology of multiple sclerosis.

Authors:  D H Adams; J P Dickinson
Journal:  Lancet       Date:  1974-06-15       Impact factor: 79.321

3.  Letter: Treatment of aphthous stomatitis.

Authors:  H Verhaegen; J De Cree; J Brugmans
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

4.  Cellular immunity and hepatitis-associated, Australia antigen liver disease.

Authors:  F J Dudley; R A Fox; S Sherlock
Journal:  Lancet       Date:  1972-04-01       Impact factor: 79.321

5.  Subtle immunologic abnormalities in four boys with subacute sclerosing panencephalitis.

Authors:  K L Gerson; R H Haslam
Journal:  N Engl J Med       Date:  1971-07-08       Impact factor: 91.245

6.  Letter: In-vitro restoration by levamisole of thymus-derived lymphocyte functions in Hodgkin's disease.

Authors:  H Verhaegen; W De Cock; J De Cree; F Verbruggen; M Verhaegen-Declercq; J Brugmans
Journal:  Lancet       Date:  1975-04-26       Impact factor: 79.321

7.  Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease.

Authors:  M Biniaminov; B Ramot
Journal:  Lancet       Date:  1975-02-22       Impact factor: 79.321

8.  Levamisole treatment of a child with severe aphthous stomatitis and neutropenia.

Authors:  H Verhaegen; J De Crée; W De Cock; J Brugmans
Journal:  Postgrad Med J       Date:  1976-08       Impact factor: 2.401

9.  Function and distribution pattern of human T lymphocytes. II. Presence of T lymphocytes in normal humans and in humans with various immunodeficiency disorders.

Authors:  F Aiuti; H Wigzell
Journal:  Clin Exp Immunol       Date:  1973-02       Impact factor: 4.330

10.  In vitro phagocytosis of Candida albicans by peripheral polymorphonuclear neutrophils of patients with recurrent infections:Case reports of serum-dependent abnormalities.

Authors:  H Verhaegen; W de Cock; J de Cree
Journal:  Biomedicine       Date:  1976-06
View more
  8 in total

1.  The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients.

Authors:  H Verhaegen; W De Cock; J De Cree
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

2.  Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes.

Authors:  L A Runge; R S Pinals; R H Tomar
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

3.  Defective neutrophil chemotaxis and raised serum ige levels in a child with recurrent bacterial infections and eczema. Influence of levamisole.

Authors:  J De Cree; L Emmery; J Timmermans; R Eeckels; W De Cock; H Verhaegen
Journal:  Arch Dis Child       Date:  1978-02       Impact factor: 3.791

4.  Thymopoietin and levamisole in chronic granulomatous inflammation.

Authors:  P A Thrower; A D Sedgwick; E R Smith; D A Willoughby; E C Huskisson
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

5.  Levamisole and HBsAg positive chronic persistent hepatitis.

Authors:  M Masi; P Paolucci; G Timoncini; M P Fantini; G Leggieri; F Chiodo; C Franceschi
Journal:  Arch Dis Child       Date:  1978-09       Impact factor: 3.791

6.  Suppression of pokeweed mitogen-induced differentiation of human B cells by in vitro levamisole-treated T lymphocytes.

Authors:  T Miyawaki; H Seki; N Moriya; T Nagaoki; M Kubo; N Okuda; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

7.  Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole.

Authors:  W De Cock; J De Cree; H Verhaegen
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

8.  A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole.

Authors:  L Businco; F Laurenti; P Rossi; E Galli; F Aiuti
Journal:  Arch Dis Child       Date:  1981-01       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.